Table 3.
Improved OA Pain Intensity and Patient's and Physician's Global Assessments of Disease Activity (ITT Population)
| Lumiracoxib 100 mg o.d. (n = 755) | Lumiracoxib 100 mg b.i.d. (n = 1,519) | Celecoxib 200 mg o.d. (n = 758) | |
| Patient's target joint pain intensity assessment | |||
| Changes in scores from baseline to study endpoint, n (%)† | |||
| Improvement | 382 (50.6) | 795 (52.3) | 406 (53.6) |
| No change | 269 (35.6) | 566 (37.3) | 265 (35.0) |
| Worsened | 104 (13.8) | 158 (10.4) | 87 (11.5) |
| Overall measure of efficacy, least squares mean‡ | 2.78 | 2.72 | 2.77 |
| Patient's global assessment of disease activity | |||
| Changes in scores from baseline to study endpoint, n (%)† | |||
| Improvement | 368 (48.7) | 768 (50.6) | 373 (49.2) |
| No change | 265 (35.1) | 534 (35.2) | 269 (35.5) |
| Worsened | 122 (16.2) | 216 (14.2) | 116 (15.3) |
| Overall measure of efficacy, least squares mean‡ | 2.61 | 2.54 | 2.60 |
| Physician's global assessment of disease activity | |||
| Changes in scores from baseline to study endpoint, n (%)† | |||
| Improvement | 411 (54.5) | 888 (58.5) | 425 (56.2) |
| No change | 244 (32.4) | 463 (30.5) | 232 (30.7) |
| Worsened | 99 (13.1) | 167 (11.0) | 99 (13.1) |
| Overall measure of efficacy, least squares mean‡ | 2.55 | 2.45* | 2.52 |
o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat; †patients with missing baseline values were not included; ‡Overall measure of efficacy defined as the weighted average of post-baseline scores using the last observation carried forward technique for missing values and time since previous visit as weight (lower scores represent better responses); *p < 0.05 vs lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.